The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.

Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to

Jinwu Financial NewsDec 18, 2024 09:50

BioNTech announced that Adcendo ApS is exercising its antibody option to accelerate ADC development.

Adcendo exercises its options to further expand its ADC pipeline using Baiaosaitu's fully human antibodies, developing new therapies for cancers with high unmet Medical needs. This collaboration further validates the potential of Baiaosaitu's independently developed RenMice antibody discovery platform in promoting innovative therapies to benefit patients. Peking, December 16, 2024 /PR Newswire/ -- Baiaosaitu (Peking) Pharmaceutical Technology Co., Ltd. (Baiaosaitu, stock code: 02315.HK), an international Biotechnology company focused on the development of novel antibody/ADC therapies, announces.

PR NewswireDec 16, 2024 18:00

Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15, 2024 12:17

Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy

MT NewswiresNov 12, 2024 18:18

PacBio-Sequencing-B (02315.HK): IDEAYA nominates B7H3/PTK7 heteromeric enzyme inhibitors with similar first-class potential as effective payload dual-specificity ADC (IDE034) as a development candidate drug and exercises its right of selection.

Grassroots on November 11th, Bai Aosai Tu-B (02315.HK) announced that IDEAYA Biosciences, Inc. (nasdaq: IDYA) (IDEAYA), a precision medical company dedicated to discovering and developing targeted therapeutic drugs for tumors, has exercised its option to obtain the global exclusive license of B7H3/PTK7 topoisomerase inhibitor payload dual-specificity antibody conjugate drug (BsADC) BCG034 (IDE034) with similar first-in-class potential to Bai Aosai Tu, and has nominated the project as a development candidate drug.

Gelonghui FinanceNov 11, 2024 18:35

Beijing Enterprises Water Group Ltd. - B (02315.HK) received shareholding of 1 million H shares from Vico (Hong Kong) Economic and Trade Limited, with a value of approximately 5.85 million Hong Kong dollars.

Reported on November 1st, according to the documents disclosed by the Hong Kong Stock Exchange on November 1st, VK (Hong Kong) Trade and Industry Co., Ltd. increased its shareholding of $1 million H-shares of Paxon-B (02315.HK) at an average price of HK$5.85 per share on October 31, worth approximately HK$5.85 million. After the shareholding increase, the latest number of shares held by VK (Hong Kong) Trade and Industry Co., Ltd. is 8.1026 million shares, and the holding ratio has increased from 6.41% to 7.31%. Image Source: Stock Exchange Equity Disclosure. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their equity.

Futu NewsNov 1, 2024 17:04